Allogene Therapeutics reports Q4 EPS (28c), consensus (32c)

Based on its cash, cash equivalents and investments as of December 31, the company continues to expect its cash runway to fund operations into the second half of 2026. Guidance for 2025 is an expected decrease in cash, cash equivalents, and investments of approximately $170 M. GAAP Operating Expenses are expected to be approximately $250M, including estimated non-cash stock-based compensation expense of approximately $50M. These estimates exclude any impact from potential business development activities.”In 2024, we focused on delivering on our bold strategy to achieve what no CAR T has accomplished before,” said David Chang, M.D., Ph.D., President, Chief Executive Officer, and Co-Founder of Allogene. “Our recent data, published in the Journal of Clinical Oncology, from the Phase 1 ALPHA/ALPHA2 trials in relapsed/refractory LBCL provided compelling evidence that cema-cel can induce durable remissions comparable to approved autologous CD19 CAR T therapies. With the ALPHA3 first line consolidation trial evaluating cema-cel in LBCL now underway, the ALLO-329 IND clearance to launch the RESOLUTION trial in autoimmune disease, and completion of the Phase 1b cohort with ALLO-316 in the TRAVERSE trial in RCC, we are demonstrating that Allogene’s vision for an “off-the-shelf” cell therapy may not just be a possibility, it could be a reality in hematology, autoimmune diseases, and solid tumors. We believe 2025 will be the year allogeneic CAR T broadly begins to demonstrate its potential to surpass autologous CAR T therapy by reaching more patients with greater accessibility.”